DiagnaMed Holdings Corp. (DMED) AI Stock Analysis

DiagnaMed Holdings Corp.

(CNQX:DMED)

Select Model

Rating:39Underperform

Price Target:CAD 0.03▲(10.00% Upside)

Action:reiterated

Date:10/15/26

The score is driven primarily by very weak financial fundamentals, including zero revenue, persistent losses, negative equity, and ongoing cash burn. Technical indicators are also unfavorable, and the negative P/E provides no valuation support. The absence of debt is a minor positive, but the overall risk profile remains extremely high.

Positive Factors

No Reported DebtAbsence of reported debt limits interest and repayment obligations, preserving more flexibility for a small company to direct scarce resources toward health-technology development. This is a relative balance-sheet advantage even though negative equity still weakens overall resilience.

Negative Factors

Pre-Revenue BusinessThe absence of reported revenue means the company has not yet demonstrated commercial traction or an internally funded operating model. Without sales, future development must be supported by external financing, making progress toward sustainable profitability dependent on successful commercialization.

DiagnaMed Holdings Corp. (DMED) vs. iShares MSCI Canada ETF (EWC)

Market Cap: CAD 3.95M
Dividend Yield: ―
Average Volume (3M): 231.03K
Price to Earnings (P/E): -1.9
Beta (1Y): 2.31
Revenue Growth: ―
EPS Growth: -28.35%
Country: Canada
Employees: 5
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

DiagnaMed Holdings Corp. Business Overview & Revenue Model

Company Description

Diagnamed Holdings Corp. engages in the development and commercialization of AI healthcare solutions. The company focuses on developing BRAIN AGE BRAIN HEALTH, a brain health AI platform leveraging that aims to predict and monitor brain age and provi...

DiagnaMed Holdings Corp. Financial Statement Overview

Summary

Extremely weak financial performance: the company is pre-revenue, has widening losses, negative equity, declining assets, and persistently negative operating and free cash flow. The absence of debt and relatively small absolute cash burn provide limited support.

Income Statement

8Very Negative

Balance Sheet

12Very Negative

Cash Flow

15Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Sep 2021
Income Statement
Total Revenue	0	0	0	0	0	0
Gross Profit	0	0	0	0	-24.71K	-16.05K
EBITDA	-1.84M	-1.40M	172.24K	-100.34K	-1.13M	-1.95M
Net Income	-1.85M	-1.40M	-501.00K	-1.28M	-1.13M	-1.95M
Balance Sheet
Total Assets	330.82K	216.36K	201.75K	662.27K	1.62M	2.39M
Cash, Cash Equivalents and Short-Term Investments	293.76K	183.83K	162.15K	606.96K	1.57M	2.36M
Total Debt	0	0	0	0	0	0
Total Liabilities	508.82K	666.47K	466.91K	426.38K	369.51K	150.24K
Stockholders Equity	-178.00K	-450.11K	-265.17K	235.89K	1.25M	2.24M
Cash Flow
Free Cash Flow	-582.73K	-336.07K	-444.82K	-1.07M	-787.58K	-565.60K
Operating Cash Flow	-582.73K	-336.07K	-444.82K	-1.07M	-787.58K	-565.60K
Investing Cash Flow	0	0	0	0	0	34.07K
Financing Cash Flow	615.02K	357.75K	0	104.25K	0	2.89M

DiagnaMed Holdings Corp. Technical Analysis

Technical Analysis SentimentNegative

Last Price0.03

Price Trends

50DMA0.04Negative

100DMA0.05Negative

200DMA0.07Negative

Market Momentum

MACD-0.00Positive

RSI43.09Neutral

STOCH-0.00Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DMED, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.04, and below the 200-day MA of 0.07, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 43.09 is Neutral, neither overbought nor oversold. The STOCH value of -0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:DMED.

DiagnaMed Holdings Corp. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

TSE:DMED against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TSE:CHS	41Neutral	CAD 10.29M	-1.76	64.52%	―	7.63%	-106.03%
TSE:UDOC	41Neutral	CAD 5.18M	-1.59	355.56%	―	614.03%	51.97%
TSE:ADK	40Underperform	CAD 40.34M	-8.11	9999.00%	―	-36.92%	13.03%
TSE:DMED	39Underperform	CAD 3.95M	-1.94	739.84%	―	―	-28.35%
TSE:AIDR	38Underperform	CAD 44.56M	-1.64	-444.52%	―	415.06%	-54.80%
TSE:NARA	38Underperform	CAD 2.39M	-0.82	184.91%	―	―	43.30%

* Healthcare Sector Average

Performance Comparison

TSE:DMED and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TSE:DMED	DiagnaMed Holdings Corp.	0.03	-0.06	-66.67%
TSE:ADK	Diagnos Inc	0.34	-0.01	-1.47%
TSE:AIDR	Rocket Doctor Ai Inc	0.44	-0.44	-50.00%
TSE:CHS	Comprehensive Healthcare Systems Inc	0.35	-0.27	-42.74%
TSE:UDOC	Unidoc Health Corp.	0.06	-0.13	-68.42%
TSE:NARA	PanGenomic Health, Inc. Class A	0.17	-1.03	-85.83%

DiagnaMed Holdings Corp. Corporate Events

Business Operations and StrategyExecutive/Board Changes

DiagnaMed reshapes board as it sharpens focus on natural clean hydrogen

Positive

Aug 24, 2026

DiagnaMed Holdings Corp. has appointed energy-law specialist Charles Turmel to its board, adding governance, regulatory and corporate finance expertise as it pivots more decisively into natural clean hydrogen. His appointment coincides with the resig...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 15, 2026

DiagnaMed Holdings Corp. AI Stock Analysis